43 results about "Cell wall synthesis" patented technology

The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with their ability to cross bacterial cell membranes makes them suitable for use as antibacterial drugs or other antibacterial applications.

Compositions and methods are provided for the use of SOS pathway targeted agents in antimicrobial formulations. The innate sensitivity of bacteria to antibiotics is increased by disrupting a mechanism that normally activates the bacterial SOS response or by inhibiting steps in the SOS response pathway itself. SOS response induction can result from exposure of bacteria to certain antibiotics, including β-lactam antibiotics and other agents that affect cell wall synthesis. By transiently delaying bacterial cell division, SOS response induction interferes with bacterial killing by ordinarily lethal concentrations of these drugs A pharmaceutical composition comprising an SOS targeted agent is administered to a patient suffering from a microbial infection, in combination with an antibiotic that induces an SOS response. The identification of the SOS pathway as a target for modulating antibiotic action provides a basis for further therapeutic development, through screening assays designed to detect molecules or genes that act on these pathways.

Methods are provided for increasing plant growth rate, biomass and tolerance to stress by genetically engineering plants to contain and express a gene of the ascorbic acid synthesis-cell wall synthesis network (e.g. GlcUA reductase, GLOase or MIOX). Transgenic plants that are genetically engineered in such a manner are also provided.

The invention relates to the use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilization or rupture of the bacterial cell wall.The invention further relates to a pharmaceutical composition for treatment of extracellular and / or intracellular microbial infected cells and / or for the prevention of microbial cell infections comprising at least one antibiotic acting as an inhibitor of bacterial RNA polymerase and / or at least one antibiotic affecting the bacterial cell wall or its synthesis, and a substrate carrying a pharmaceutical composition.The invention also relates to the use of a combination of at least one antibiotic acting as an inhibitor of bacterial RNA polymerase and at least one antibiotic affecting the bacterial cell wall or its synthesis as anti-adhesive against microorganisms on surfaces.

The invention discloses a construction method for double-gene mutation escherichia coli used for secretory expression of recombinant protein. According to the invention, pre-designed primers for the double-knockout-genes of cell membrane protein and cell wall synthetase gene are used for a PCR reaction so as to obtain gene targeting fragments of the double-knockout-gene, wherein two ends of each gene targeting fragment are 10 to 250 bp homologous sequences of a specific target gene and the middle part of each gene targeting fragment is a resistance labeled sequence; the fragments are respectively integrated into chromosomes of the host escherichia coli through electrotransformation so as to obtain a secretory double-gene mutation escherichia coli strain. The method provided by the invention increases the expression of recombinant exogenous proteins, reduces intracellular degradation of target proteins, decreases intracellular accumulation of the recombinant exogenous proteins and eradicates formation of inclusion bodies; the method discards a breaking process for cell walls, reduces pyrogen and simplifies separation and purification; thus, the purposes of reducing production cost and improving protein expression and product quality are achieved.

The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts.

A method of rapidly evaluating the susceptibility of a strain of bacteria to a cell wall synthesis inhibiting antibiotic based on an assessment of cell enlargement in response to doses of the cell wall synthesis inhibiting antibiotic which are correlated to breakpoints of bacterial susceptibility.

The invention discloses a plant gene promoter and its application. The base sequence of the promoter is shown in SEQ ID NO:1. Tobacco transgenic experiments proved that pGhGlcat1 can endow high-level expression of GUS reporter gene in epidermal trichomes, apical meristem region, and stamens and pistils of plant floral organs, indicating that GhGlcat1 plays a role in cotton fiber primary cell wall synthesis, cell elongation, floral organ development and stress The functional study of pGhGlcat1 provides clues for revealing the expression regulation mechanism of GhGlcat1. In addition, pGhGlcat1 can also be used in the genetic engineering improvement of plant quality and resistance.

A C-terminus modification to a binding pocket-modified vancomycin introduces a quaternary ammonium salt that provides a binding pocket-modified vancomycin analog with a second mechanism of action that is independent of D-Ala-D-Ala / D-Ala-D-Lac binding. The modification disrupts cell wall integrity and induces cell wall permeability complementary to the glycopeptide inhibition of cell wall synthesis, and provides synergistic improvements in antimicrobial potency (200-fold) against vancomycin-resistant bacteria. Combining the C-terminus and binding pocket modifications with an orthogonal (4-chlorobiphenyl) methyl addition to the vancomycin disaccharide provides even more potent antimicrobial agents whose activity can be attributed to three independent and synergistic mechanisms of action, only one of which requires D-Ala-D-Ala / D-Ala-D-Lac binding. The resulting modified vancomycins display little propensity for acquired resistance through serial exposure of vancomycin-resistant Enterococci and their durability against such challenges as well as their antimicrobial potency follow predicable trends. Methods of treatment with and compositions containing the modified vancomycins are disclosed.

A method of antibiotic susceptibility testing is disclosed, and includes the following steps: (A) providing a sample to be tested wherein the sample contains a microbe; (B) adding an antibiotic into the sample, wherein the antibiotic serves to inhibit cell wall synthesis; (C) checking the sample by dielectrophoresis and observing a shape change of the microbe; and (D) determining whether the microbe is susceptible to the antibiotic according to the shape change thereof. The present invention also discloses a method for determining a minimum inhibitory concentration of the antibiotic.